{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"82.9","value":"1294"},{"groupId":"OG002","spread":"59.3","value":"1872"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Cycle 1 week 1 day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"86.8","value":"1711"},{"comment":"Here, \"NA\" indicates that data could not be evaluated due to smaller number of participants.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"62.9","value":"1984"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Cycle 1 week 2 day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"71.5","value":"1490"},{"comment":"Here, \"NA\" indicates that data could not be evaluated due to smaller number of participants.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"88.2","value":"2643"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"title":"Cycle 1 week 3 day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.9","value":"1885"},{"groupId":"OG002","spread":"89.0","value":"1899"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Cycle 2 day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"description":"The plasma PK of AZD4573 when administered in participants was assessed.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG000","title":"Cohort 1 Non-NK PTCL"},{"description":"Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG001","title":"Cohort 2 NK PTCL"},{"description":"Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG002","title":"Cohort 3 cHL"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK set included all participants who received any amount of study intervention with at least 1 reportable concentration. Here, 'n\" (number analyzed in each row) signifies the participants with available data that were analyzed for each timepoint of this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (Cycle length is 35 days), Day 1 of Weeks 1-3 and Cycle 2 (Cycle length is 21 Days), Day 1.","title":"Area Under Plasma Concentration Time Curve From Zero to Infinity (AUC0-inf) of AZD4573","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}